DAM
ATNM icon

DLD Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

DLD Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-134,000
Closed -$426K – 117
2018
Q1 		$426K Buy
+134,000
New +$2.28M 0.04% 83

Other funds holding ATNM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

DLD Asset Management's ATNM Position: Q2 2019 in Review

DLD Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2019, closing a stake of 4,689 shares — an estimated $68K sold.

DLD Asset Management first reported a position in ATNM in Q1 2018 and held it in 5 quarters. The position peaked at $2.11M in Q2 2018. 44 funds tracked by Wall St. Rank hold ATNM as of Q2 2019.

  • DLD Asset Management reported no remaining Actinium Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • DLD Asset Management sold 4,689 Actinium Pharmaceuticals shares in Q2 2019, an estimated $68K.
  • DLD Asset Management first reported a position in Actinium Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • DLD Asset Management's Actinium Pharmaceuticals position peaked at $2.11M in Q2 2018.
  • 44 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2019.

Based on DLD Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.